Immunome, Inc. (IMNM) NASDAQ
19.34
-1.44(-6.93%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
19.34
-1.44(-6.93%)
Currency In USD
Address
665 Stockton Drive
Bothell, PA 19341
United States of America (the)
Phone
610 321 3700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
131
First IPO Date
October 02, 2020
| Name | Title | Pay | Year Born |
| Clay Siegall | Chairman, President & Chief Executive Officer | 1.41M | 1961 |
| Kinney Horn | Chief Business Officer | 598,862 | 1975 |
| Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary | 715,350 | 1973 |
| Robert J. Lechleider | Chief Medical Officer | 850,093 | 1961 |
| Jack Higgins | Chief Scientific Officer | 956,342 | 1980 |
| Max Rosett | Chief Financial Officer | 1.16M | 1990 |
| Philip Tsai | Chief Technical Officer | 0 | 1968 |
| Roee Shahar | Executive Vice President of Commercial | 0 | N/A |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.